“…62 In terms of Zoster vaccine (Zostavax, Merck, USA), this vaccine is recommended as a 1-time vaccination in individuals aged 60 years or older, and although it is clear that immunosuppression increases the risk of herpes zoster, there is a paucity of studies aimed at understanding the benefits and risks of administering this vaccine in this special population. 59 Tseng et al recently reported how older patients who receive the zoster vaccine were likely to continue to derive its benefits even if they become immunosuppressed; however, the study was not able to determine zoster vaccine safety or effectiveness in cancer patients who received zoster vaccine less than 60 days before beginning chemotherapy. 65,66 This study emphasizes the need to vaccinate immunocompetent patients older than 60 years of age, as currently no recommendations can be done about Zostavax vaccination in immunocompromised individuals.…”